SION-109
Cystic Fibrosis (F508del mutation)
PreclinicalLead Optimization
Key Facts
Indication
Cystic Fibrosis (F508del mutation)
Phase
Preclinical
Status
Lead Optimization
Company
About Sionna Therapeutics
Sionna Therapeutics is advancing a pipeline of next-generation cystic fibrosis correctors designed to fully restore CFTR function in patients with the prevalent F508del mutation. The company's lead program, SION-638, is in Phase 1 clinical trials, with a portfolio of follow-on candidates targeting distinct mechanisms. Sionna's strategy is to develop combination therapies that could offer superior clinical benefit compared to current standards of care, addressing a significant unmet need in the CF patient population.
View full company profileTherapeutic Areas
Other Cystic Fibrosis (F508del mutation) Drugs
| Drug | Company | Phase |
|---|---|---|
| SION-638 | Sionna Therapeutics | Phase 1 |
| SION-451 | Sionna Therapeutics | Preclinical |
| SION-676 | Sionna Therapeutics | Preclinical |